Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tablet and capsule interchangeability as solid oral dosage forms urged by Perrigo.

This article was originally published in The Tan Sheet

Executive Summary

TABLET, CAPSULE INTERCHANGEABILITY AS SOLID ORAL DOSAGE FORM URGED by private label manufacturer Perrigo. The firm also suggests that FDA consider tablets and capsules as the same (i.e., solid oral) dosage forms as caplets, "Penta"-shaped tablets (i.e., J&J/Merck's Pepcid AC) or other shaped tablets, the company maintains in June 26 comments to the agency. The company was responding to an FDA request for comments on whether there should be any change in agency policy to limit permitting bioequivalent tablets and capsules to be listed as "therapeutically equivalent" in the "Orange Book" or should FDA regard tablets and capsules as the same (solid, oral).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel